MIRM — Mirum Pharmaceuticals, Inc. stock price, charts and financials

QT49Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
91.83
-6.99-7.07%
OverviewShort InterestFilings
MIRMQT49Mirum Pharmaceuticals, Inc.·NASDAQ
91.83-7.07%
News
Down 7.1% — MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains? (Yahoo).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
SRRK-4.83%$46.65LGND-0.42%$283.49ORKA-2.83%$94.96PTCT-3.87%$65.37CRSP-1.34%$56.56DNTH-4.26%$96.81COGT-5.09%$31.50TVTX-3.06%$62.76
Snapshot
Index-P/E-EPS (ttm)-14.56Insider Own40.47%Shs Outstand60.98MPerf Week-6.51%
Market Cap5.60BForward P/E-EPS next Y-0.76Insider Trans-0.74%Shs Float52.46MPerf Month-10.18%
Enterprise Value6.03BPEG0.00EPS next Q-0.53Inst Own-Short Float11.76%Perf Quarter-14.28%
Income-827.67MP/S9.06EPS this Y-3.92%Inst Trans-Short Ratio7.85Perf Half Y1.22%
Sales618.07MP/B-EPS next Y94.97%ROA-82.32%Short Interest6.17MPerf YTD16.26%
Book/sh-P/C-EPS next 5Y-ROE-410.20%52W High130.00 -29.36%Perf Year25.55%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-13.09%52W Low63.23 45.23%Perf 3Y206.51%
Dividend Est.-EV/EBITDA-Sales past 3/5Y89.14% -Gross Margin81.70%Volatility4.70% 3.92%Perf 5Y405.95%
Dividend TTM-EV/Sales9.76EPS Y/Y TTM-687.03%Oper. Margin-17.42%ATR (14)4.20Perf 10Y-
Dividend Ex-Date-Quick Ratio2.74Sales Y/Y TTM83.38%Profit Margin-139.18%RSI (14)37.01Recom1.94
Dividend Gr. 3/5Y-Current Ratio2.86EPS Q/Q-783.33%SMA20-6.29%Beta0.61Target Price140.20
Payout0.00%Debt/Eq-Sales Q/Q37.50%SMA50-11.91%Rel Volume2.36Prev Close98.82
Employees433LT Debt/Eq1.01EarningsNov 03SMA200-5.55%Avg Volume760.38KPrice91.83
IPO DateJul 18, 2019Option/ShortYes / YesEPS/Sales Surpr.-42.75% 5.93%Net Debt/EBITDA-0.55Volume1,797,930Change-7.07%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-27-26ReiteratedUBS$140 → $137
Aug-06-26ReiteratedRobert W. Baird$129 → $123
Aug-06-26ReiteratedMorgan StanleyOverweight$150 → $137
Aug-06-26ReiteratedHC Wainwright & Co.Buy$185 → $140
Aug-06-26ReiteratedRBC CapitalOutperform$148 → $135
Jul-07-26ReiteratedRBC CapitalOutperform$142 → $148
Jun-15-26ReiteratedCLSA$146
Jun-11-26ReiteratedMorgan StanleyOverweight$140 → $150
May-19-26InitiatedWolfe ResearchOutperform$145
May-07-26ReiteratedRaymond JamesStrong Buy$164 → $165
Latest News· Times ET
Sep-17-26
Sep-17-2606:44PM
MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains?Yahoo
Sep-16-26
Sep-16-2609:01AM
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com
08:12AM
Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Eventsseekingalpha.com
Sep-14-26
Sep-14-2612:01PM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com
Sep-10-26
Sep-10-2610:17AM
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcriptseekingalpha.com
Sep-08-26
Sep-08-2604:30AM
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officerbusinesswire.com
Sep-04-26
Sep-04-2608:37AM
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?zacks.com
Sep-02-26
Sep-02-2612:01PM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferencesbusinesswire.com
Aug-31-26
Aug-31-2610:57AM
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should KnowSeekingAlpha
Aug-27-26
Aug-27-2606:01AM
Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price TargetBenzinga
Aug-25-26
Aug-25-2612:09AM
BlackRock Inc. Takes $513.95 Million Position in Mirum Pharmaceuticals, Inc. $MIRMdefenseworld.net
Aug-23-26
Aug-23-2611:53PM
Deutsche Bank AG Purchases New Holdings in Mirum Pharmaceuticals, Inc. $MIRMdefenseworld.net
Aug-19-26
Aug-19-2612:14AM
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade)SeekingAlpha
Aug-11-26
Aug-11-2612:01PM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com
Aug-06-26
Aug-06-2611:52AM
TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140Benzinga
Company

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue618521337——————
Cost of Goods Sold Incl. D&A11310182——————
Gross Profit505421255——————
Selling, General and Administrative Excl. Other313257202——————
Research and Development283186141——————
Other Operating Expense
1600——————
Operating Income-108-22-88——————
Interest Expense151414——————
Unusual Expense
—————————
Non-Operating Income (Expense)-7361515——————
Net Income Before Taxes-858-21-87——————
Income Taxes321——————
Consolidated Net Income-860-23-88——————
Net Income From Continuing Operations-860-23-88——————
Net Income-860-23-88——————
EPS (Recurring)-14.56-0.47-1.85——————
EPS (Basic, Before Extraordinaries)-14.56-0.47-1.85——————
EPS (Diluted)-14.56-0.47-1.85——————
EBITDA-77617-49——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio9.367.585.89——————
Gross Margin81.7280.8175.67——————
Operating Margin-17.48-4.22-26.11——————
Net Margin-139.16-4.41-26.11——————
Shares Outstanding635048——————
Market Capitalization5,7853,9491,985——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$140.19$115.02$89.84$64.67$39.50● Close Price0.00M2.25M4.50M6.75M9.00MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
BJERKHOLT ERICCHIEF FINANCIAL OFFICERSep 14 '26Sale98.379,943978,09344,745Sep 15
BJERKHOLT ERICCHIEF FINANCIAL OFFICERSep 11 '26Option Exercise0.0018,333054,688Sep 15
Howe JolandaSVP, GLOBAL CONTROLLERSep 02 '26Sale100.0065865,800616Sep 03
Peetz ChristopherCHIEF EXECUTIVE OFFICERSep 01 '26Option Exercise2.9430,00088,080224,440Sep 03
Peetz ChristopherCHIEF EXECUTIVE OFFICERSep 01 '26Sale98.6830,0002,960,401194,440Sep 03
Howe JolandaSVP, GLOBAL CONTROLLERAug 18 '26Option Exercise6.2740,000250,80041,274Aug 19
Howe JolandaSVP, GLOBAL CONTROLLERAug 18 '26Sale100.0040,0004,000,0001,274Aug 19
BJERKHOLT ERICCHIEF FINANCIAL OFFICERAug 11 '26Sale99.906,001599,51036,355Aug 12
Peetz ChristopherCHIEF EXECUTIVE OFFICERAug 10 '26Sale98.9220,0001,978,401194,309Aug 11
Peetz ChristopherCHIEF EXECUTIVE OFFICERAug 10 '26Option Exercise2.9420,00058,720214,309Aug 11
Howe JolandaSVP, GLOBAL CONTROLLERAug 03 '26Sale105.291,840193,7341,274Aug 05
Peetz ChristopherCHIEF EXECUTIVE OFFICERJul 06 '26Option Exercise2.9420,00058,720214,309Jul 08
Peetz ChristopherCHIEF EXECUTIVE OFFICERJul 06 '26Sale122.2720,0002,445,383194,309Jul 08
BJERKHOLT ERICCHIEF FINANCIAL OFFICERJul 06 '26Sale122.255,000611,27442,181Jul 08
Howe JolandaSVP, GLOBAL CONTROLLERJul 01 '26Sale120.002,721326,5203,114Jul 02
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.